Mouse models to study the effect of cardiovascular risk factors on brain structure and cognition

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 11, 2013, Pages 1666-1684

  Bink, Diewertje I ^a,b   Ritz, Katja ^a   Aronica, Eleonora ^a,c,d   Van Der Weerd, Louise ^b   Daemen, Mat Jap ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

animal models; cerebral blood flow; inflammation; vascular cognitive impairment

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; CD45 ANTIGEN; CYCLOPHILIN A; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN;

ALZHEIMER DISEASE; AORTA CONSTRICTION; ASTROCYTE; ATHEROSCLEROSIS; BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN PERFUSION; BRAIN REGION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; COGNITION; COGNITIVE DEFECT; COMMON CAROTID ARTERY; DENDRITIC CELL; DISEASE ASSOCIATION; ENCEPHALITIS; GRAY MATTER; HEART FAILURE; HEART INFARCTION; HUMAN; KNOCKOUT MOUSE; MEMORY DISORDER; MICROGLIA; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; SPATIAL MEMORY; SYNAPTIC TRANSMISSION; TRANSVERSE AORTIC CONSTRICTION; VASCULAR COGNITIVE IMPAIRMENT; WHITE MATTER LESION;

AGING; ANIMALS; BRAIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR CIRCULATION; COGNITION; DISEASE MODELS, ANIMAL; MICE;

EID: 84887083328     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.140     Document Type: Review

References (150)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75, e2.
2. Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995; 310: 970-973.
3. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 2672-2713.
4. Prince M. Epidemiology of dementia. Psychiatry 2007; 6: 488-490. (Pubitemid 350186268)
5. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail 2007; 9: 440-449. (Pubitemid 46561483)
6. Skoog I. Hypertension and cognition. Int Psychogeriatr 2003; 15(Suppl 1): 139-146. (Pubitemid 37175181)
7. Bos D, Vernooij MW, Elias-Smale SE, Verhaaren BF, Vrooman HA, Hofman A et al. Atherosclerotic calcification relates to cognitive function and to brain changes on magnetic resonance imaging. Alzheimers Dement 2012; 8: S104-S111.
8. Wendell CR, Waldstein SR, Ferrucci L, O'Brien RJ, Strait JB, Zonderman AB. Carotid atherosclerosis and prospective risk of dementia. Stroke 2012; 43: 3319-3324.
9. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 2006; 166: 1003-1008.
10. van Oijen M, De Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol 2007; 61: 403-410. (Pubitemid 46878768)
11. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007; 64: 1734-1740. (Pubitemid 350254935)
12. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012; 2012: 367516.
13. Marshall RS. Effects of altered cerebral hemodynamics on cognitive function. J Alzheimers Dis 2012; 32: 633-642.
14. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005; 57: 789-794. (Pubitemid 40798616)
15. Kitagawa K. Cerebral blood flow measurement by PET in hypertensive subjects as a marker of cognitive decline. J Alzheimers Dis 2010; 20: 855-859.
16. Kitagawa K, Oku N, Kimura Y, Yagita Y, Sakaguchi M, Hatazawa J et al. Relationship between cerebral blood flow and later cognitive decline in hypertensive patients with cerebral small vessel disease. Hypertens Res 2009; 32: 816-820.
17. van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly. J Cereb Blood Flow Metab 2008; 28: 1071-1085. (Pubitemid 351733344)
18. Roman DD, Kubo SH, Ormaza S, Francis GS, Bank AJ, Shumway SJ. Memory improvement following cardiac transplantation. J Clin Exp Neuropsychol 1997; 19: 692-697. (Pubitemid 28005010)
19. Zuccala G, Onder G, Marzetti E, Monaco MR, Cesari M, Cocchi A et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005; 26: 226-233. (Pubitemid 40222360)
20. Hoth KF, Poppas A, Ellison KE, Paul RH, Sokobin A, Cho Y et al. Link between change in cognition and left ventricular function following cardiac resynchronization therapy. J Cardiopulm Rehabil Prev 2010; 30: 401-408.
21. Cheng Y, Wang YJ, Yan JC, Zhou R, Zhou HD. Effects of carotid artery stenting on cognitive function in patients with mild cognitive impairment and carotid stenosis. Exp Ther Med 2013; 5: 1019-1024.
22. Vogels RL, van der Flier WM, van Harten B, Gouw AA, Scheltens P, Schroeder-Tanka JM et al. Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 2007; 9: 1003-1009. (Pubitemid 47451813)
23. Romero JR, Beiser A, Seshadri S, Benjamin EJ, Polak JF, Vasan RS et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke 2009; 40: 1590-1596.
24. Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the preclinical development of drugs for stroke? Trends Neurosci 2007; 30: 433-439. (Pubitemid 47374833)
25. Samaranayake S. Study Quality in Experimental Stroke. University of Edinburgh: Edinburgh, 2006.
26. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cerebr Blood F Met 2005; 25: 713-721. (Pubitemid 40705606)
27. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005; 38: 35-41. (Pubitemid 40139308)
28. Macleod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004; 35: 1203-1208. (Pubitemid 38543544)
29. Lukasik VM, Gillies RJ. Animal anaesthesia for in vivo magnetic resonance. NMR Biomed 2003; 16: 459-467. (Pubitemid 38072565)
30. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
31. Daugherty A. Mouse models of atherosclerosis. Am J Med Sci 2002; 323: 3-10. (Pubitemid 34650115)
32. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
33. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-140.
34. Methia N, Andre P, Hafezi-Moghadam A, Economopoulos M, Thomas KL, Wagner DD. ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med 2001; 7: 810-815. (Pubitemid 34175304)
35. Sheng H, Laskowitz DT, Mackensen GB, Kudo M, Pearlstein RD, Warner DS. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. Stroke 1999; 30: 1118-1124. (Pubitemid 29211636)
36. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012; 485: 512-516.
37. Drake C, Boutin H, Jones MS, Denes A, McColl BW, Selvarajah JR et al. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun 2011; 25: 1113-1122.
38. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 2011; 286: 17536-17542.
39. Hafezi-Moghadam A, Thomas KL, Wagner DD. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am J Physiol Cell Physiol 2007; 292: C1256-C1262. (Pubitemid 46631730)
40. Mulder M, Blokland A, van den Berg DJ, Schulten H, Bakker AH, Terwel D et al. Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest 2001; 81: 953-960. (Pubitemid 32645971)
41. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol 2001; 169: 13-22. (Pubitemid 32427699)
42. Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 2009; 5: 634-645.
43. Yang CP, Gilley JA, Zhang G, Kernie SG. ApoE is required for maintenance of the dentate gyrus neural progenitor pool. Development 2011; 138: 4351-4362.
44. Krugers HJ, Mulder M, Korf J, Havekes L, de Kloet ER, Joels M. Altered synaptic plasticity in hippocampal CA1 area of apolipoprotein E deficient mice. Neuro-Report 1997; 8: 2505-2510. (Pubitemid 27308451)
45. Valastro B, Ghribi O, Poirier J, Krzywkowski P, Massicotte G. AMPA receptor regulation and LTP in the hippocampus of young and aged apolipoprotein E-deficient mice. Neurobiol Aging 2001; 22: 9-15. (Pubitemid 32332993)
46. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 1995; 136: 107-122.
47. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T et al. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/-mice: isoformspecific effects on neurodegeneration. J Neurosci 1999; 19: 4867-4880.
48. Grootendorst J, de Kloet ER, Dalm S, Oitzl MS. Reversal of cognitive deficit of apolipoprotein E knockout mice after repeated exposure to a common environmental experience. Neuroscience 2001; 108: 237-247. (Pubitemid 33152965)
49. Grootendorst J, Oitzl MS, Dalm S, Enthoven L, Schachner M, de Kloet ER et al. Stress alleviates reduced expression of cell adhesion molecules (NCAM, L1), and deficits in learning and corticosterone regulation of apolipoprotein E knockout mice. Eur J Neurosci 2001; 14: 1505-1514. (Pubitemid 35463717)
50. Grootendorst J, Enthoven L, Dalm S, de Kloet ER, Oitzl MS. Increased corticosterone secretion and early-onset of cognitive decline in female apolipoprotein E-knockout mice. Behav Brain Res 2004; 148: 167-177. (Pubitemid 37543665)
51. Veinbergs I, Mallory M, Mante M, Rockenstein E, Gilbert JR, Masliah E. Differential neurotrophic effects of apolipoprotein E in aged transgenic mice. Neurosci Lett 1999; 265: 218-222. (Pubitemid 29207405)
52. Veinbergs I, Mante M, Jung MW, Van Uden E, Masliah E. Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 519-531. (Pubitemid 29274221)
53. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489-1499. (Pubitemid 32038587)
54. Genis L, Chen Y, Shohami E, Michaelson DM. Tau hyperphosphorylation in apolipoprotein E-deficient and control mice after closed head injury. J Neurosci Res 2000; 60: 559-564. (Pubitemid 30252919)
55. Katsouri L, Georgopoulos S. Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model. PLoS One 2011; 6: e21880.
56. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997; 17: 263-264.
57. Purcell-Huynh DA, Farese Jr. RV, Johnson DF, Flynn LM, Pierotti V, Newland DL et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995; 95: 2246-2257.
58. Csont T, Bereczki E, Bencsik P, Fodor G, Gorbe A, Zvara A et al. Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice. Cardiovasc Res 2007; 76: 100-109. (Pubitemid 47362048)
59. Bereczki E, Bernat G, Csont T, Ferdinandy P, Scheich H, Santha M. Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J Proteome Res 2008; 7: 2246-2252.
60. Hobbs HH, Brown MS, Russell DW, Davignon J, Goldstein JL. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987; 317: 734-737. (Pubitemid 17138204)
61. Oliveira JD, Hort MA, Moreira EL, Glaser V, Ribeiro-do-Valle RM, Prediger RD et al. Positive correlation between elevated plasma cholesterol levels and cognitive impairments in LDL receptor knockout mice: relevance of cortico-cerebral mitochondrial dysfunction and oxidative stress. Neuroscience 2011; 197: 99-106.
62. Elder GA, Cho JY, English DF, Franciosi S, Schmeidler J, Sosa MA et al. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J Neurochem 2007; 102: 1220-1231. (Pubitemid 47174226)
63. Taha AY, Chen CT, Liu Z, Kim JH, Mount HT, Bazinet RP. Brainstem concentrations of cholesterol are not influenced by genetic ablaqtion of the low-density lipoprotein receptor. Neurochem Res 2009; 34: 311-315.
64. Osono Y, Woollett LA, Herz J, Dietschy JM. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J Clin Invest 1995; 95: 1124-1132.
65. Franciosi S, Gama Sosa MA, English DF, Oler E, Oung T, Janssen WG et al. Novel cerebrovascular pathology in mice fed a high cholesterol diet. Mol Neurodegener 2009; 4: 42.
66. Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS et al. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem 2008; 106: 475-485. (Pubitemid 351840227)
67. Mulder M, Jansen PJ, Janssen BJ, van de Berg WD, van der Boom H, Havekes LM et al. Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol Dis 2004; 16: 212-219. (Pubitemid 38569812)
68. Mulder M, Koopmans G, Wassink G, Al Mansouri G, Simard ML, Havekes LM et al. LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus. Neurosci Res 2007; 59: 251-256. (Pubitemid 47503374)
69. Elder GA, Ragnauth A, Dorr N, Franciosi S, Schmeidler J, Haroutunian V et al. Increased locomotor activity in mice lacking the low-density lipoprotein receptor. Behav Brain Res 2008; 191: 256-265.
70. Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem 2005; 280: 25754-25759. (Pubitemid 40962285)
71. Cao D, Fukuchi K, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 2006; 27: 1632-1643. (Pubitemid 44344838)
72. Sanan DA, Newland DL, Tao R, Marcovina S, Wang J, Mooser V et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci USA 1998; 95: 4544-4549.
73. Drouin A, Bolduc V, Thorin-Trescases N, Belanger E, Fernandes P, Baraghis E et al. Catechin treatment improves cerebrovascular flow-mediated dilation and learning abilities in atherosclerotic mice. Am J Physiol Heart Circ Physiol 2011; 300: H1032-H1043.
74. Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, Ross J et al. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998; 4: 934-938. (Pubitemid 28364033)
75. Ramirez C, Sierra S, Tercero I, Vazquez JA, Pineda A, Manrique T et al. ApoB100/LDLR-/-hypercholesterolaemic mice as a model for mild cognitive impairment and neuronal damage. PLoS One 2011; 6: e22712.
76. Bolduc V, Drouin A, Gillis MA, Duquette N, Thorin-Trescases N, Frayne-Robillard I et al. Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice. Am J Physiol Heart Circ Physiol 2011; 301: H2081-H2092.
77. Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis 2011; 24: 269-285.
78. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D et al. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 18787-18792. (Pubitemid 44913488)
79. Poulet R, Gentile MT, Vecchione C, Distaso M, Aretini A, Fratta L et al. Acute hypertension induces oxidative stress in brain tissues. J Cereb Blood Flow Metab 2006; 26: 253-262. (Pubitemid 43151580)
80. Gentile MT, Poulet R, Di Pardo A, Cifelli G, Maffei A, Vecchione C et al. Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 2009; 30: 222-228.
81. Chintalgattu V, Ai D, Langley R, Zhang J, Bankson J, Shih T et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 2010; 120: 472-484.
82. Nakamura A, Rokosh D, Paccanaro M, Yee R, Simpson P, Grossman W et al. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol 2001; 281: H1104-H1112.
83. Li YH, Hsieh CY, Wang DL, Chung HC, Liu SL, Chao TH et al. Remodeling of carotid arteries is associated with increased expression of thrombomodulin in a mouse transverse aortic constriction model. Thromb Haemost 2007; 97: 658-664. (Pubitemid 46592944)
84. Li YH, Reddy AK, Taffet GE, Michael LH, Entman ML, Hartley CJ. Doppler evaluation of peripheral vascular adaptations to transverse aortic banding in mice. Ultrasound Med Biol 2003; 29: 1281-1289. (Pubitemid 37211328)
85. Carnevale D, Mascio G, Ajmone-Cat MA, D'Andrea I, Cifelli G, Madonna M et al. Role of neuroinflammation in hypertension-induced brain amyloid pathology. Neurobiol Aging 2012; 33: 205, e19-e29.
86. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I et al. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 2012; 60: 188-197.
87. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B et al. A multimodal RAGEspecific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122: 1377-13792.
88. Yang J, Noyan-Ashraf MH, Meissner A, Voigtlaender-Bolz J, Kroetsch JT, Foltz W et al. Proximal cerebral arteries develop myogenic responsiveness in heart failure via tumor necrosis factor-alpha-dependent activation of sphingosine-1-phosphate signaling. Circulation 2012; 126: 196-206.
89. Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, Fujita Y et al. A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 2010; 41: 1278-1284.
90. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 2004; 35: 2598-2603. (Pubitemid 39458424)
91. Shibata M, Yamasaki N, Miyakawa T, Kalaria RN, Fujita Y, Ohtani R et al. Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke 2007; 38: 2826-2832. (Pubitemid 47494024)
92. Nakaji K, Ihara M, Takahashi C, Itohara S, Noda M, Takahashi R et al. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke 2006; 37: 2816-2823. (Pubitemid 44922545)
93. Fujita Y, Ihara M, Ushiki T, Hirai H, Kizaka-Kondoh S, Hiraoka M et al. Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke 2010; 41: 2938-2943.
94. Duan W, Gui L, Zhou Z, Liu Y, Tian H, Chen JF et al. Adenosine A2A receptor deficiency exacerbates white matter lesions and cognitive deficits induced by chronic cerebral hypoperfusion in mice. J Neurol Sci 2009; 285: 39-45.
95. Coltman R, Spain A, Tsenkina Y, Fowler JH, Smith J, Scullion G et al. Selective white matter pathology induces a specific impairment in spatial working memory. Neurobiol Aging 2011; 32: e7-e12.
96. Yamada M, Ihara M, Okamoto Y, Maki T, Washida K, Kitamura A et al. The influence of chronic cerebral hypoperfusion on cognitive function and amyloid beta metabolism in APP overexpressing mice. PLoS One 2011; 6: e16567.
97. Dong YF, Kataoka K, Toyama K, Sueta D, Koibuchi N, Yamamoto E et al. Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension 2011; 58: 635-642.
98. Maki T, Ihara M, Fujita Y, Nambu T, Miyashita K, Yamada M et al. Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice. Stroke 2011; 42: 1122-1128.
99. Miki K, Ishibashi S, Sun L, Xu H, Ohashi W, Kuroiwa T et al. Intensity of chronic cerebral hypoperfusion determines white/gray matter injury and cognitive/motor dysfunction in mice. J Neurosci Res 2009; 87: 1270-1281.
100. Okamoto Y, Yamamoto T, Kalaria RN, Senzaki H, Maki T, Hase Y et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012; 123: 381-394.
101. Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN et al. Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res 2009; 1294: 202-210.
102. Wallays G, Nuyens D, Silasi-Mansat R, Souffreau J, Callaerts-Vegh Z, Van Nuffelen A et al. Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Arterioscler Thromb Vasc Biol 2011; 31: 2881-2888.
103. Lacombe P, Oligo C, Domenga V, Tournier-Lasserve E, Joutel A. Impaired cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy arteriopathy. Stroke 2005; 36: 1053-1058. (Pubitemid 40629302)
104. Ayata C. CADASIL: experimental insights from animal models. Stroke 2010; 41: S129-S134.
105. Joutel A, Monet-Lepretre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 2010; 120: 433-445.
106. el Azzouzi H, van Oort RJ, van der Nagel R, Sluiter W, Bergmann MW, De Windt LJ. MEF2 transcriptional activity maintains mitochondrial adaptation in cardiac pressure overload. Eur J Heart Fail 2010; 12: 4-12.
107. Mahley RW, Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 2012; 76: 871-885.
108. Ostergaard L, Aamand R, Gutierrez-Jimenez E, Ho YC, Blicher JU, Madsen SM et al. The capillary dysfunction hypothesis of Alzheimer's disease. Neurobiol Aging 2012; 34: 1018-1031.
109. de la Torre JC. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 2008; 5: 126-132. (Pubitemid 351347829)
110. Desmond DW. The neuropsychology of vascular cognitive impairment: is there a specific cognitive deficit? J Neurol Sci 2004; 226: 3-7. (Pubitemid 39505397)
111. Voss SE, Bullock RA. Executive function: the core feature of dementia? Dement Geriatr Cogn Disord 2004; 18: 207-216. (Pubitemid 39140372)
112. Muir ER, Shen Q, Duong TQ. Cerebral blood flow MRI in mice using the cardiacspin-labeling technique. Magn Reson Med 2008; 60: 744-748.
113. Apostolova I, Wunder A, Dirnagl U, Michel R, Stemmer N, Lukas M et al. Brain perfusion SPECT in the mouse: normal pattern according to gender and age. NeuroImage 2012; 63: 1807-1817.
114. Ayata C, Dunn AK, Gursoy OY, Huang Z, Boas DA, Moskowitz MA. Laser speckle flowmetry for the study of cerebrovascular physiology in normal and ischemic mouse cortex. J Cereb Blood Flow Metab 2004; 24: 744-755. (Pubitemid 38880219)
115. Adam JF, Elleaume H, Le Duc G, Corde S, Charvet AM, Tropres I et al. Absolute cerebral blood volume and blood flow measurements based on synchrotron radiation quantitative computed tomography. J Cereb Blood Flow Metab 2003; 23: 499-512. (Pubitemid 36403032)
116. Shang Y, Chen L, Toborek M, Yu G. Diffuse optical monitoring of repeated cerebral ischemia in mice. Opt Express 2011; 19: 20301-20315.
117. Shih AY, Driscoll JD, Drew PJ, Nishimura N, Schaffer CB, Kleinfeld D. Two-photon microscopy as a tool to study blood flow and neurovascular coupling in the rodent brain. J Cereb Blood Flow Metab 2012; 32: 1277-1309.
118. Holland PR, Bastin ME, Jansen MA, Merrifield GD, Coltman RB, Scott F et al. MRI is a sensitive marker of subtle white matter pathology in hypoperfused mice. Neurobiol Aging 2011; 32: 2325, e1-e6.
119. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154-169.
120. Stolp HB, Dziegielewska KM. Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol 2009; 35: 132-146.
121. Zhu P, Ren M, Yang C, Hu YX, Ran JM, Yan L. Involvement of RAGE, MAPK and NF-kappaB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol 2012; 21: 123-129.
122. Kim ES, Kim JS, Kim SG, Hwang S, Lee CH, Moon A. Sphingosine 1-phosphate regulates matrix metalloproteinase-9 expression and breast cell invasion through S1P3-Galphaq coupling. J Cell Sci 2011; 124: 2220-2230.
123. Kida K, Minamishima S, Wang H, Ren J, Yigitkanli K, Nozari A et al. Sodium sulfide prevents water diffusion abnormality in the brain and improves long term outcome after cardiac arrest in mice. Resuscitation 2012; 83: 1292-1297.
124. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM et al. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 2004; 35: e159-e162.
125. Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62: 1734-1736. (Pubitemid 41626671)
126. Flex A, Gaetani E, Proia AS, Pecorini G, Straface G, Biscetti F et al. Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2006; 61: 1065-1069. (Pubitemid 44727215)
127. Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg GA, Jaworski DM. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci 2010; 30: 15337-15357.
128. Huntley GW. Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci 2012; 13: 743-757.
129. Michaluk P, Wawrzyniak M, Alot P, Szczot M, Wyrembek P, Mercik K et al. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 2011; 124: 3369-3380.
130. Badaut J, Copin JC, Fukuda AM, Gasche Y, Schaller K, da Silva RF. Increase of arginase activity in old apolipoprotein E deficient mice under Western diet associated with changes in neurovascular unit. J Neuroinflamm 2012; 9: 132.
131. Bugnicourt JM, Da Silveira C, Bengrine A, Godefroy O, Baumbach G, Sevestre H et al. Chronic renal failure alters endothelial function in cerebral circulation in mice. Am J Physiol Heart Circ Physiol 2011; 301: H1143-H1152.
132. Kitayama J, Faraci FM, Lentz SR, Heistad DD. Cerebral vascular dysfunction during hypercholesterolemia. Stroke 2007; 38: 2136-2141. (Pubitemid 47012280)
133. Yamashiro K, Milsom AB, Duchene J, Panayiotou C, Urabe T, Hattori N et al. Alterations in nitric oxide and endothelin-1 bioactivity underlie cerebrovascular dysfunction in ApoE-deficient mice. J Cereb Blood Flow Metab 2010; 30: 1494-1503.
134. Lynch JR, Pineda JA, Morgan D, Zhang L, Warner DS, Benveniste H et al. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol 2002; 51: 113-117. (Pubitemid 34027983)
135. McDaniel B, Sheng H, Warner DS, Hedlund LW, Benveniste H. Tracking brain volume changes in C57BL/6J and ApoE-deficient mice in a model of neurodegeneration: a 5-week longitudinal micro-MRI study. NeuroImage 2001; 14: 1244-1255. (Pubitemid 33124173)
136. Anderson R, Barnes JC, Bliss TV, Cain DP, Cambon K, Davies HA et al. Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience 1998; 85: 93-110. (Pubitemid 28228418)
137. Fagan AM, Murphy BA, Patel SN, Kilbridge JF, Mobley WC, Bu G et al. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Exp Neurol 1998; 151: 314-325.
138. Rahman A, Akterin S, Flores-Morales A, Crisby M, Kivipelto M, Schultzberg M et al. High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 2005; 579: 6411-6416. (Pubitemid 41612160)
139. Grootendorst J, de Kloet ER, Vossen C, Dalm S, Oitzl MS. Repeated exposure to rats has persistent genotype-dependent effects on learning and locomotor activity of apolipoprotein E knockout and C57Bl/6 mice. Behav Brain Res 2001; 125: 249-259. (Pubitemid 33000463)
140. Xi L, Ghosh S, Wang X, Das A, Anderson FP, Kukreja RC. Hypercholesterolemia enhances tolerance to lethal systemic hypoxia in middle-aged mice: possible role of VEGF downregulation in brain. Mol Cell Biochem 2006; 291: 205-211. (Pubitemid 44725319)
141. Yi CX, Al-Massadi O, Donelan E, Lehti M, Weber J, Ress C et al. Exercise protects against high-fat diet-induced hypothalamic inflammation. Physiol Behav 2012; 106: 485-490.
142. Moreira EL, de Oliveira J, Nunes JC, Santos DB, Nunes FC, Vieira DS et al. Age-related cognitive decline in hypercholesterolemic LDL receptor knockout mice (LDLr-/-): evidence of antioxidant imbalance and increased acetylcholinesterase activity in the prefrontal cortex. J Alzheimers Dis 2012; 32: 495-511.
143. Norman GJ, Karelina K, Berntson GG, Morris JS, Zhang N, Devries AC. Heart rate variability predicts cell death and inflammatory responses to global cerebral ischemia. Front Physiol 2012; 3: 131.
144. Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I et al. Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway.
145. Yoshizaki K, Adachi K, Kataoka S, Watanabe A, Tabira T, Takahashi K et al. Chronic cerebral hypoperfusion induced by right unilateral common carotid artery occlusion causes delayed white matter lesions and cognitive impairment in adult mice. Exp Neurol 2008; 210: 585-591.
146. Lee JS, Im DS, An YS, Hong JM, Gwag BJ, Joo IS. Chronic cerebral hypoperfusion in a mouse model of Alzheimer's disease: an additional contributing factor of cognitive impairment. Neurosci Lett 2011; 489: 84-88.
147. Kitagawa K, Yagita Y, Sasaki T, Sugiura S, Omura-Matsuoka E, Mabuchi T et al. Chronic mild reduction of cerebral perfusion pressure induces ischemic tolerance in focal cerebral ischemia. Stroke 2005; 36: 2270-2274. (Pubitemid 41429258)
148. Ma J, Xiong JY, Hou WW, Yan HJ, Sun Y, Huang SW et al. Protective effect of carnosine on subcortical ischemic vascular dementia in mice. CNS Neurosci Ther 2012; 18: 745-753.
149. Pimentel-Coelho PM, Michaud JP, Rivest S. Effects of mild chronic cerebral hypoperfusion and early amyloid pathology on spatial learning and the cellular innate immune response in mice. Neurobiol Aging 2013; 34: 679-693.
150. Reimer MM, McQueen J, Searcy L, Scullion G, Zonta B, Desmazieres A et al. Rapid disruption of axon-glial integrity in response to mild cerebral hypoperfusion. J Neurosci 2011; 31: 18185-18194.